Proof of efficacy of Kamillosan(R) cream in atopic eczema.
Kamillosan(R) cream contains chamomile extract as active principle manufactured from the chamomile sort Manzana which is rich in active principles and has been proved not to exhibit a chamomile-related allergen potential. For this reason Kamillosan(R) cream is suited for local therapy of atopic eczema. In a partially double-blind, randomized study carried out as a half-side comparison, Kamillosan(R) cream was tested vs. 0.5% hydrocortisone cream and the vehicle cream as placebo in patients suffering from medium-degree atopic eczema. After a 2-week treatment Kamillosan(R) cream showed a mild superiority towards 0.5% hydrocortisone and a marginal difference as compared to placebo.
Patzelt-Wenczler
R
R
ASTA Medica AG, Weismüllerstr. 45, D-60314 Frankfurt am Main, Germany. Dr_Jeannette.Simon@astamedica.de
Ponce-Pöschl
E
E
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D016718:Arachidonic Acid / Q000378:metabolism; D001132:Arm; D020843:Chamomile / Q000627:therapeutic use; D003876:Dermatitis, Atopic / Q000188:drug therapy*; D004338:Drug Combinations; D004890:Erythema / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008875:Middle Aged; D009822:Oils, Volatile / Q000008:administration & dosage*; D008517:Phytotherapy; D010936:Plant Extracts / Q000008:administration & dosage*; D010946:Plants, Medicinal; D011537:Pruritus / Q000188:drug therapy; D012717:Sesquiterpenes / Q000008:administration & dosage*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D009822:Oils, Volatile; D010936:Plant Extracts; D012717:Sesquiterpenes; C056251:Kamillosan; D016718:Arachidonic Acid; D006854:Hydrocortisone